Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by Red~Oneon Jan 14, 2023 6:50pm

399 Views

Post# 35223602

O/T Looks like Tuesday

911

0
23 minutes ago

"OTC Markets has informed me that $GVSI is set to be deemed Pink Limited on Tuesday. Don't ask me, ask your broker. — George Sharp - CEO of FORW, SRNW, WNFT & GVSI (@GeorgeASharp) January 13, 2023"

0
8 minutes ago

$GVSI is preparing an initial court action to cancel over 294 million shares. Records are being examined to determine how many additional shares might be cancelled. — George Sharp - CEO of FORW, SRNW, WNFT & GVSI (@GeorgeASharp) January 14, 2023